A Randomized Comparative Study of High Dose CPA/cDDP/BCNU and ABMT versus Standard Dose CPA/cDDP/BCNU as Consolidation to Adjuvant CAF for Patients with Operable Stage II or Stage III Breast Cancer Involving > 10 Axillary Lymph Nodes, Phase III

Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082

LB Marks;C Cirrincione;TJ Fitzgerald;F Laurie;AS Glicksman;J Vredenburgh;LR Prosnitz;EJ Shpall;M Crump;PG Richardson;MW Schuster;J Ma;BL Peterson;L Norton;S Seagren;IC Henderson;DD Hurd;WP Peters Int. J. Radiat. Oncol. Biol. Phys. 76(5):1305-1313

PMid: PMID19747781 | PMC number: PMC3670136

Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13

WP Peters;GL Rosner;JJ Vredenburgh;EJ Shpall;M Crump;PG Richardson;MW Schuster;LB Marks;C Cirrincione;L Norton;IC Henderson;RL Schilsky;DD Hurd Journal of Clinical Oncology 23(10):2191-200

Updated results of a prospective, randomized comparison of two doses of combination alkyating agents (AA) as consolidation after CAF in high-risk primary breast ca involving 10 or more axillary lymph nodes: CALGB 9082/SWOG 9114/NCIC Ma-13

WP Peters;G Rosner;J Vredenburgh;E Shpall;M Crump;L Marks;C Cirrincione;D Hurd;L Norton Proc of the American Society of Clinical Oncology 20:21a(#81)

A prospective, randomized comparison of two doses od combination alkyating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): preliminary results of CALGB 9082/ SWOG 9114/NCIC MA-13

W Peters;G Rosner;J Vredenburgh;E Shpall;M Crump;P Richardson;L Marks;C Cirrincione;W Wood;I Henderson;D Hurd;L Norton Proc of the American Society of Clinical Oncology 18:1a(#2)